Aura Biosciences

Update in progress

AURA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision therapies for solid tumors. Its platform uses virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. The lead candidate, bel-sar, is in late-stage development for primary choroidal melanoma and other ocular oncology indications, and in early-stage trials for bladder cancer. Founded in 2009, the company is based in Boston, Massachusetts.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.77; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.18; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.38; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.44; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive